2015 ASCO Journal Club:
Breast Cancer First Quarter
Each quarter, ASCO’s experts review the leading journals, including the Journal of Clinical Oncology, to compile the most relevant, practice-changing science in breast cancer. Reviews are presented in a didactic slide format, with audio commentary and links to references and resources and will focus on the following areas: translational science, clinical trials, reviews, guidelines, and editorials.
Articles covered in this quarter’s review include:
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Sikov et al. J Clin Oncol. 2015 Jan 1;33(1):13-21.
- Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. Francis et al. N Engl J Med 2015; 372:436-446.
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Finn et al. Lancet Oncol. 2015 Jan;16(1):25-35
Learning Objectives
- Review the impact of including carboplatin in the neoadjuvant chemotherapy of triple negative breast cancer on pathologic complete response rate and understand the toxicities associated with inclusion of carboplatin.
- Examine the evidence that has lead to the recent approval of palbociclib in combination with letrozole as first line therapy for metastatic estrogen receptor positive breast cancer and understand the toxicities associated with palbociclib therapy.
- Recognize the benefit and adverse events associated with the use of ovarian suppression in combination with tamoxifen or aromatase inhibitors as adjuvant therapy for premenopausal women and identify the patient population that is most appropriate for combined ovarian suppression and antiestrogen therapy.
- Apply knowledge learned to enhance the care delivered to patients with breast cancer.
1 AMA PRA Category 1 Credit(s) ™ CME credit is available for this course. The CME credit for this course will expire March 25, 2018.
ACGME Competencies addressed: Medical Knowledge
Note: This course is now accessible through iPads as well as personal computers.
ACGME Competencies addressed: Medical Knowledge
Note: This course is now accessible through iPads as well as personal computers.
No comments:
Post a Comment